Skip to content

Total debt at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$1.43B+138%
UroGen Pharma logo
UroGen PharmaURGN
$197.09M+56.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.26B+32,101%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$419K+204%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350.49M+4.2%
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.79B+318%
Enterprise value$1.71B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $5.7M.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s total debt?
Tyra Biosciences, Inc. (TYRA) reported total debt of $5.7M in Q1 2026.
How has Tyra Biosciences, Inc.'s total debt changed year-over-year?
Tyra Biosciences, Inc.'s total debt decreased by 6.9% year-over-year, from $6.12M to $5.7M.
What is the long-term trend for Tyra Biosciences, Inc.'s total debt?
Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s total debt has grown at a 107.5% compound annual growth rate (CAGR), from $151K to $5.81M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.